VSTM Share Price

Open 3.67 Change Price %
High 3.85 1 Day 0.16 4.37
Low 3.64 1 Week 0.00 0.00
Close 3.82 1 Month -0.53 -12.18
Volume 430787 1 Year 2.57 205.60
52 Week High 5.71
52 Week Low 1.05
VSTM Important Levels
Resistance 2 4.01
Resistance 1 3.93
Pivot 3.77
Support 1 3.71
Support 2 3.63
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Verastem, Inc. (NASDAQ: VSTM)

VSTM Technical Analysis 1.5
As on 31st Oct 2017 VSTM Share Price closed @ 3.82 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.50 & Sell for SHORT-TERM with Stoploss of 4.28 we also expect STOCK to react on Following IMPORTANT LEVELS.
VSTM Target for November
1st Target up-side 4.64
2nd Target up-side 5.21
3rd Target up-side 5.78
1st Target down-side 3
2nd Target down-side 2.43
3rd Target down-side 1.86
VSTM Other Details
Segment EQ
Market Capital 171709120.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.verastem.com
VSTM Address
VSTM
215 First Street
Suite 440
Cambridge, MA 02142
United States
Phone: 617-252-9300
VSTM Latest News
Interactive Technical Analysis Chart Verastem, Inc. ( VSTM NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Verastem, Inc.
VSTM Business Profile
Verastem, Inc. is a clinical biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. The Company also develops companion diagnostics. The Company has technology to create a stable population of cancer stem cells that it uses to screen for and identify small molecule compounds that target cancer stem cells. The Company�s advanced programs target the Focal Adhesion Kinase (FAK), and the PI3K/mTOR signaling pathways. The Company�s lead FAK inhibitor, VS-6063, is in Phase 1/1b testing in ovarian cancer. The Company�s solution is to discover and develop an oncology therapeutics targeting CSCs along with companion diagnostics. The Company is focused on the discovery and development of small molecules to allow flexibility in the design of molecules for optimized efficacy and safety primarily as orally available drug candidates.